

Avectas Limited

Technology:

Solupore™ is the next generation cell engineering technology for ex vivo immune cell therapy.

Website:

www.avectas.com

Company Outline:

- Founded: 2012
- Employees: 18

Investors:

- Private

Management Team:**Dr. Michael Maguire, CEO**

- Founder
- Clinical Engineer
- Serial entrepreneur
- 20 years experience

Dr. Shirley O’Dea, CSO

- Founder
- Biologist
- Group Leader, PI
- 20 years experience

Dr. Mary Martin, Chair

- Pharmacologist
- 30 years technology & product development experience

Locations:

- Dublin, Ireland
- Cambridge, Massachusetts

Scientific Advisory Board:

- Prof. D. Anderson: MIT, Langer Lab
- Dr. P. Burke: Merck, Amgen
- Prof. R. Curry: UC Davis
- Dr. B. Kleinstiver: Harvard
- Prof. M. Lowdell: UCL

Professional Advisors:

- Auditors: KPMG
- Patent Attorneys: Mintz Levin Partners, Boston
- Attorneys Ireland: Byrne Wallace

Intracellular Delivery for Next Generation Cell Therapies

Business:

- Avectas is a biotechnology company developing Solupore™, a novel cell engineering technology enabling drug developers to overcome challenges in the manufacture of cell therapies. Solupore™ delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of primary cell types including T cells for immuno-oncology and gene editing applications.
- Avectas is partnering with immuno-oncology and gene editing businesses to deliver their proprietary molecules. Avectas is additionally seeking therapeutic molecules to in-license as the core of a therapeutic program.

Technology:

- Vector-free delivery platform aligned with cGMP manufacturing process.
- Solupore™ is the combination of a patent-pending cell manufacturing device and proprietary reagents which together enable versatile, vector free cell engineering.
- Simple, rapid, gentle process yields superior engineered cells.
- Improved cell processing times and cell health, post engineering, relative to viral vectors and electroporation.
- Addresses immuno-oncology applications including CAR-T and gene editing.
- For mRNA and other advanced cargos delivered to primary immune cells, Avectas is building a comprehensive dataset around delivery performance including; efficiency, cell viability, functionality, proliferative capacity, process yield, molecular profiles showing shorter processing times and healthier cells.

IP:

- 1 Patent Granted, 8 Patents applied for.
- Registered Trade Marks; Avectas® and Solupore™

Market:

- Avectas address the cell immunotherapy market valued at US\$20bn by 2027 (Market & Market).
- CAR-T and Gene Editing the fastest growing segment with >800 clinical trials

Competition:

- Electroporation and Nucleofection systems, Viral delivery

Contact:

Dr. Michael Maguire: mmaguire@avectas.com